Reports
Global Peptide Therapeutics Market Size, Forecast: By Type: Branded Peptide, Generics Peptide; By Applications: Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Others; By Route of Administration; By Type of Manufactures; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031
Global Peptide Therapeutics Market Outlook
The global peptide therapeutics market value was USD 36.1 billion in 2022, driven by the rising advancements in peptide synthesis technologies across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2023-2031 to achieve a value of USD 69.9 billion by 2031.
The Oral Segment to Hold a Significant Share in the Global Peptide Therapeutics Industry
The oral segment based on the route of administration is expected to account for a significant share in the market. The growing efforts by the drug developers to facilitate oral delivery of peptides due to the increased inclination of people towards minimally invasive treatments are likely to boost the segment growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Additionally, orally delivered peptide therapeutics facilitate patient compliance, diversify the treatment options, offer ease of administration, and boost marketability. These factors are likely to aid the market growth. Moreover, the expansion of the major biotechnology companies specialising in the oral delivery of peptides is anticipated to bolster the market growth in the forecast period.
North America Accounts for a Significant Share in the Market
The peptide therapeutics industry in North America is driven by factors such as the strong pharmaceutical and biopharmaceutical ecosystem in the region, easy access to medical facilities, and rapid growth in the development of therapeutic proteins. A considerable increase in the number of protein-based drugs, coupled with the increased investments to develop new therapeutic proteins for a wide range of ailments has supported the regional market expansion. In addition, the favourable government policies encouraging the sales of peptide-based drugs are anticipated to further aid the market growth in the region.
Peptide Therapeutics: Market Segmentation
Peptide therapeutics can be defined as peptide-based therapeutics used to treat various diseases. Peptide therapeutics mimic the functions of the naturally occurring peptides in the human body, further serving as a promising basis for targeting a range of diseases. They are often well tolerated by the body and have the potential for decreased off-target side effects.
Based on marketing type, the market has been segmented into:
- Generic
- Branded
The segmentation of the market based on application is as follows:
- Gastrointestinal Disorders
- Neurological Disorders
- Metabolic Disorders
- Cancer
- Cardiovascular
- Others
On the basis of route of administration, the market is divided into:
- Parenteral
- Oral
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Rising Cases of Chronic Diseases, coupled with the Increasing Prevalence of Cancer to Boost the Growth of the Peptide Therapeutics Industry
The rising cases of chronic diseases and the increasing prevalence of cancer are driving the global peptide therapeutics industry. Additionally, there has been a significant surge in the incidences of metabolic diseases such as diabetes among the geriatric population. Unhealthy and poor lifestyles led by people with hectic and busy schedules are likely to increase the risk of various kinds of diseases, thereby enhancing the therapeutic use of peptide drugs for different treatments. Hence, these factors are likely to provide impetus to the peptide therapeutics industry. The complexity associated with large peptides is likely to restrain the market growth, however, the growing availability of biosimilars is expected to aid the market in the forecast period.
Key Industry Players in the Global Peptide Therapeutics Market
The report gives a detailed analysis of the following key players in the global peptide therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis AG
- Amgen Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup byType |
|
| Breakup by Applications |
|
| Breakup by Route of Administration |
|
| Breakup by Type of Manufactures |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Peptide Therapeutics Market Overview
3.1 Global Peptide Therapeutics Market Historical Value (2016-2022)
3.2 Global Peptide Therapeutics Market Forecast Value (2023-2031)
4 Global Peptide Therapeutics Market Landscape
4.1 Global Peptide Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Peptide Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Distribution Channel
4.2.3 Analysis by Applications
5 Global Peptide Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Peptide Therapeutics Market Segmentation
6.1 Global Peptide Therapeutics Market by Type
6.1.1 Market Overview
6.1.2 Branded Peptide
6.1.3 Generics Peptide
6.2 Global Peptide Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Cancer, Cardiovascular Disease
6.2.3 Metabolic Disease
6.2.4 Respiratory Disease
6.2.5 Infectious Disease
6.2.6 Others
6.3 Global Peptide Therapeutics Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.2.1 Tablets
6.3.2.2 Capsules
6.3.3 Parenteral
6.3.3.1 Intravascular
6.3.3.2 intramuscular
6.4 Global Peptide Therapeutics Market by Type of Manufactures
6.4.1 Market Overview
6.4.2 In House
6.4.3 Outsourced
6.5 Global Peptide Therapeutics Market by Distribution Channels
6.5.1 Market Overview
6.5.2 Hospitals Pharmacies
6.5.3 Retail Pharmacies
6.5.4 Online Pharmacies
6.5.5 Others
6.6 Global Peptide Therapeutics Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Peptide Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Peptide Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Peptide Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Peptide Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Peptide Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 F. Hoffmann-La Roche Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 GlaxoSmithKline plc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sanofi
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Takeda Pharmaceutical Company Limited
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Teva Pharmaceutical Industries Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Ipsen Pharma
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 AstraZeneca
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Lonza
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Merck Sharp & Dohme Corp.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Novo Nordisk A/S
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 PolyPeptide Group
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 CordenPharma International
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Peptide Therapeutics Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The peptide therapeutics were valued at USD 36.1 billion in 2022.
The market is expected to grow at a CAGR of 7.6% from 2023 to 2031 to reach a value of USD 69.9 billion by 2031.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the industry, such as the rising cases of chronic diseases such as cancer and tuberculosis, advancements in the field of medical science, and the growing healthcare spending, are expected to fuel the market growth.
The key market trends guiding the growth of the industry include the growing investments by the leading life sciences companies in research and development activities.
Generic and branded are the major marketing types considered within the market report.
Gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and cardiovascular, among others are the different applications of peptide therapeutics.
Parenteral, and oral, among others are the different routes of administration utilised in the industry.
The major players in the industry are Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, and Amgen Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER